We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesArtivion Inc

Artivion Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
20.15 USD 0.05 ( 0.25%)
Last update at 2026-11-12T15:44:00Z
VOLUME
131208
Market Cap
1881.64M
P/E
184.76

Momentum Score

…

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
20.05
Low
20.77
High
52 Week Price Range
23.04
Low
48.25
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Artivion Inc makes biologic implants and surgical devices for cardiac, vascular and thoracic procedures. Long-term growth may be driven by aging populations, international expansion and new product approvals that could support recurring implant and consumable revenue. Investors may find the company attractive for its specialized portfolio and exposure to a clinical niche with higher barriers to entry.

Key risks include regulatory and reimbursement uncertainty, competition from larger medtech companies, execution challenges in manufacturing and international scaling, and sensitivity of procedure volumes to broader healthcare trends.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
20.10
Dividend Yield
-
Revenue TTM
441.33M
Revenue Per Share
9.73
Gross Profit TTM
284.23M
Debt / Equity
0.65
ROE
2.70%
Net Debt
227.13M
ROCE
3.41%
Diluted EPS TTM
0.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 14.78M -7.51M -21.59M -14.98M -14.83M
Net income 9.77M -13.36M -30.69M -19.19M -14.83M
Selling general administrative 226.49M 190.68M 183.50M 157.44M 169.77M
Selling and marketing expenses - 1.70M 1.90M - -
Gross profit 270.45M 248.78M 229.18M 202.52M 197.51M
Reconciled depreciation 22.46M 24.20M 22.69M 22.44M 23.98M
Ebit 26.75M 26.76M 3.71M 3.24M -13.86M
Ebitda 49.20M 50.97M 26.79M 25.68M 10.11M
Depreciation and amortization 22.46M 24.20M 23.08M 22.44M 23.98M
Non operating income net other - - - -2.96M -6.06M
Operating income 26.75M 38.87M 5.74M 3.24M -13.86M
Other operating expenses 414.58M 349.66M 348.26M 307.59M 306.64M
Interest expense 26.58M 34.28M 25.30M 18.22M 16.89M
Tax provision 5.01M 5.84M 6.83M 4.21M 0.01M
Interest income 0.76M 1.47M 0.74M 0.15M 0.08M
Net interest income -25.82M -32.81M -23.68M -18.08M -16.81M
Income tax expense 5.01M 5.84M 9.10M 4.21M 0.01M
Total revenue 441.33M 388.54M 354.00M 313.79M 298.84M
Total operating expenses 243.71M 209.91M 223.43M 196.32M 205.32M
Cost of revenue 170.88M 139.76M 124.83M 111.27M 101.32M
Total other income expense net -11.96M -46.39M -27.33M -18.22M -0.96M
Net income from continuing ops 9.77M -13.36M -24.55M -19.19M -14.83M
Net income applicable to common shares - - - -19.19M -14.83M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 884.80M 789.10M 792.40M 762.80M 793.05M
Intangible assets 156.50M 156.38M 172.23M 182.65M 201.50M
Other current assets 42.54M 70.96M 65.61M 17.55M 57.61M
Total liab 436.56M 512.90M 510.62M 478.47M 492.32M
Total stockholder equity 448.23M 276.20M 281.78M 284.33M 300.73M
Deferred long term liab - - - 29.97M 34.75M
Other current liab 80.14M 40.63M 35.28M 7.74M 1.08M
Common stock 0.49M 0.43M 0.43M 0.42M 0.41M
Capital stock 0.49M 0.43M 0.43M 0.42M 0.41M
Retained earnings -51.50M -61.27M -47.91M -17.22M 1.98M
Other liab - - - 77.39M 90.64M
Good will 254.09M 240.96M 247.34M 243.63M 250.00M
Other assets - - - 8.65M 10.62M
Cash 64.91M 53.46M 58.94M 39.35M 55.01M
Total current liabilities 101.56M 66.82M 57.86M 49.67M 44.95M
Current deferred revenue - - 3.84M 24.50M 28.17M
Net debt 227.13M 308.80M 299.40M 317.48M 307.03M
Short term debt 5.38M 5.29M 5.43M 5.43M 5.31M
Short long term debt - 0.20M 1.45M 1.61M 1.63M
Short long term debt total 292.04M 362.26M 358.34M 356.83M 362.04M
Other stockholder equity 501.96M 361.96M 341.27M 322.74M 308.23M
Property plant equipment - - - 38.67M 83.23M
Total current assets 303.55M 290.08M 280.67M 247.33M 247.70M
Net tangible assets - - - -141.95M -150.77M
Net receivables 103.68M 85.89M 74.14M 69.58M 58.10M
Long term debt 215.11M 314.15M 305.53M 306.50M 307.49M
Inventory 92.43M 79.77M 81.98M 74.48M 76.97M
Accounts payable 16.04M 17.97M 13.32M 12.00M 10.39M
Accumulated other comprehensive income -2.72M -24.93M -12.01M -21.61M -9.89M
Common stock total equity - - - 0.42M 0.41M
Retained earnings total equity - - - -17.22M 1.98M
Non currrent assets other 69.77M 24.48M 8.89M 7.34M 8.27M
Non current assets total 581.25M 499.02M 511.73M 515.46M 545.36M
Capital lease obligations 42.50M 47.91M 51.36M 48.72M 52.92M
Long term debt total - - - 306.50M 307.49M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -28.19M -0.50M -10.71M 5.66M
Change to liabilities - - - -1.96M -1.89M
Total cashflows from investing activities -42.04M -28.19M -0.50M -10.71M 5.66M
Net borrowings -2.46M -0.36M -5.30M -2.75M -3.08M
Total cash from financing activities 13.03M 2.20M 0.86M -1.64M -12.22M
Change to operating activities - - - -2.23M -1.40M
Net income 9.77M -13.36M -30.69M -19.19M -14.83M
Change in cash 11.45M -5.48M 19.59M -15.66M -6.95M
Begin period cash flow 53.46M 58.94M 39.35M 55.01M 61.96M
End period cash flow 64.91M 53.46M 58.94M 39.35M 55.01M
Total cash from operating activities 38.13M 22.24M 18.82M -5.15M -2.58M
Depreciation 22.46M 24.20M 23.08M 22.44M 23.98M
Other cashflows from investing activities -3.00M -17.00M 6.93M -1.70M -0.25M
Change to inventory -15.28M -6.14M -14.36M -8.40M -18.38M
Change to account receivables -7.27M -15.39M -4.05M -13.34M -11.56M
Sale purchase of stock 0.00M 0.00M -0.56M -1.79M -1.91M
Other cashflows from financing activities 2.42M -3.17M 4.20M -0.46M -7.22M
Change to netincome - - - 5.73M 21.50M
Capital expenditures 39.04M 11.19M 7.43M 10.71M 13.09M
Change receivables - - - -13.34M -11.56M
Cash flows other operating - - - 9.57M 11.90M
Cash and cash equivalents changes - - - -17.51M -9.15M
Change in working capital -22.16M -17.24M -16.19M -25.94M -33.23M
Stock based compensation 24.39M 14.24M 14.42M 12.34M 10.71M
Other non cash items 3.64M 15.90M 29.59M 6.91M 15.26M
Free cash flow -0.91M 11.05M 11.39M -15.87M -15.68M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AORT
Artivion Inc		 0.05
0.25%		 20.15 184.76 62.89 4.26 4.20 4.70 32.50
ABT
Abbott Laboratories		 -0.71
0.65%		 108.58 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.28
0.28%		 101.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -2.16
0.68%		 316.63 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 47.31 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

1655 Roberts Boulevard NW, Kennesaw, GA, United States, 30144

770 419 3355

https://artivion.com

1800

Name Title Year Born
Mr. James Patrick Mackin Chairman, Pres & CEO 1967
Mr. David Ashley Lee CPA, CPA Exec. VP, COO & CFO 1965
Ms. Jean F. Holloway Esq. Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. 1957
Mr. John E. Davis Sr. VP of Global Sales & Marketing 1965
Dr. Marshall S. Stanton M.D. Sr. VP of Clinical Research & Chief Medical Officer 1957
Ms. Amy D. Horton CPA, CPA VP & Chief Accounting Officer 1970
Mr. Matthew A. Getz VP of HR 1969
Mr. Dennis B. Maier Sr. VP of Operations 1974
Joshua Wells Sr. Director of Bus. Devel. NA
Mr. James Patrick Mackin Chairman, President & CEO 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…